Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Still going today also.
Some recovery this.
Will it hold on Friday evening...maybe
Though it might have pulled back today with profit taken.
Still pushing on...let's see where we finish on Friday close.
Well I would assume all going well that we would make a big % on sales .
Big market .
.5 billion
So dilution hopefully will be worth it in the end.
Trials start 2nd quarter 23
Summit plans to start treating patients in clinical studies by the second quarter of 2023.
The company also announced a $500 million rights offering and the issuance of $520 million in promissory notes.
https://www.reuters.com/business/healthcare-pharmaceuticals/summit-therapeutics-signs-up-5-bln-licensing-deal-experimental-cancer-therapy-2022-12-06/
Yes amazing bit of news I for one didn't see coming.
Looks like this licensing deal is liked by market...87% up now.
Very hard to watch now...where from here?
Long way back to $10
Summit Therapeutics Inc. (NASDAQ:SMMT) shares rose 60% to $1.60 in pre-market trading. Summit Therapeutics CFO Ankur Dhingra recently acquired a total of 36,215 shares at an average price of $0.97
Nova will return to what they were doing pre covid as regards earnings plus cash.
Covid as regards mass testing has been over for some time now.
Staff will have to be cut and budgets sorted.
A good little earner but not at covid leaves.
Didn't think I'd see it.
Held too long.
https://www.marketwatch.com/investing/stock/smmt
Ridinilazole failed to show superiority to vancomycin, an old antibiotic used to treat C. difficile infections.
Long way back now I'm afraid.
One of the best run companies out there.
??
Yes I get ya.
But hopefully going forward the fda may give summit some slack due to covid.
But in any case I'll wait out this trial .
Good luck .
https://www.fiercebiotech.com/biotech/fda-objects-to-summit-s-midstudy-pooling-pivotal-trials
'That bet has received a frosty reception from the FDA. “The FDA does not agree with the change to the primary endpoint that Summit proposed and has subsequently implemented in its ongoing phase 3 Ri-CoDIFy studies when combining the studies,” Summit said in a statement. '
Looks like covid will delay into next year.
News not far now .